Brain Fog, MTHFR, and the Detox Bottleneck: Sarah M.'s Recovery Story

The patient

Sarah M. (pseudonym, 32, marketing director, no children, no chronic illness on chart, no documented COVID infection) presented in October 2025 with twelve months of:

• Gradual onset brain fog that worsened through the day
• Word-finding difficulty — pausing mid-sentence, reaching for common nouns
• Afternoon energy crashes severe enough to nap at her desk
• Mild but persistent anxiety she didn't have a year prior
• Sleep onset insomnia that responded poorly to magnesium and melatonin
• Mild depression — not clinical, but "I don't feel like me"

She had been worked up by:

• Her PCP — labs fine, "stress"
• A neurologist — clean MRI, clean EEG, normal exam
• A psychiatrist — offered an SSRI, she declined
• Two wellness influencer programs — generic gut and adrenal protocols, no improvement
• A naturopath — methylated multivitamin, made her anxiety worse, stopped

Her family history included a sister with similar symptoms in her late 20s who eventually self-managed.

The intake she finally got

The workup that should have happened in month two of her symptoms:

Genetics: Compound heterozygous MTHFR (C677T + A1298C), slow COMT (Val158Met +/+), GST M1 null, SOD2 variant. That's a methylation/detox profile that runs fine in low-load environments and decompensates under sustained stress.

Overview of enzyme activity loss

How much MTHFR enzyme activity is reduced by the most common genotype combinations — the biological reason methylation, detox, and neurotransmitter clearance struggle in these patients.

Genotype Combination	Status	Approx. Enzyme Activity Reduction
C677T (C/T)	Heterozygous	35% Reduction
C677T (T/T)	Homozygous	70% – 80% Reduction
A1298C (A/C)	Heterozygous	20% Reduction
A1298C (C/C)	Homozygous	30% – 40% Reduction
C677T (C/T) + A1298C (A/C)	Compound Heterozygous	40% – 55% Reduction

Reductions are approximate ranges from the peer-reviewed MTHFR literature. Enzyme activity is one input to overall methylation capacity — COMT, MTR/MTRR, B2/B6/B12 status, and stress load all modify how the phenotype expresses.

Functional labs:

• DUTCH complete — elevated 4-OH and 16-OH estrogen metabolites (methylation lag)
• Organic acids — elevated quinolinic acid, depressed kynurenic acid (neuroinflammation pattern)
• GI-MAP — low diversity, mild SIBO pattern, low secretory IgA
• Mycotoxin urine — clean
• Reactivated-virus panel — clean (this is the COVID rule-out)
• Microclot screening — clean
• Iron studies — ferritin 18 (low end of "normal," well below optimal for cognitive function in this profile)
• Vitamin D — 22 ng/mL (deficient)
• B12 — 410 pg/mL ("normal," but with her MTHFR profile, functionally deficient)
• Homocysteine — 12.4 (elevated, methylation-cycle marker)

Pattern read: Methylation cycle stalled at the MTHFR → SAMe step. Catecholamines and estrogens accumulating as their methylated-but-not-cleared intermediates because COMT is slow. Neuroinflammation marker (quinolinic acid) elevated. Iron, D, functional B12 all low. Gut diversity collapsed from a year of stress and underrecovery.

<!-- CHART: Sarah's methylation cycle bottleneck — where each polymorphism stalls the pathway -->

This is not Long COVID. This is a methylation-detox capacity collapse under chronic stress in a genetically predisposed patient. Same label of brain fog — completely different work.

The protocol — sequenced, not stacked

Weeks 1–4 — Foundation and drainage.

• Hydration + electrolyte protocol
• Bowel mobility first — magnesium citrate dosed to one easy daily BM, soluble fiber
• Bile flow + Phase II support — taurine, glycine, milk thistle
• Iron repletion — bisglycinate paired with vitamin C, taken away from coffee/tea
• Vitamin D + K2 — therapeutic loading dose, then maintenance
• Nervous-system baseline — HRV training, daily 20-minute parasympathetic protocol (breathwork + cold exposure short-form)

Weeks 5–8 — Methylation, dosed correctly.

• B2 (riboflavin-5-phosphate) — cofactor for MTHFR, started first because slow COMT patients tolerate it better than methyl-folate alone
• Methylcobalamin — low dose, titrated up over 3 weeks (not the "start with 5mg" approach that wrecks slow-COMT patients)
• Methylfolate — added after week 6, low-dose, with adenosylcobalamin to keep the cycle balanced
• Magnesium glycinate + glycine — buffer COMT load, support sleep
• Phosphatidylserine evening dose for cortisol curve

The previous naturopath's mistake was starting at full methyl-B dose in a slow-COMT patient. We started cofactors first, methyls slow, and her sleep was the early-warning indicator we titrated against.

Weeks 9–16 — Neuroinflammation + gut.

• Targeted antioxidants — NAC, ALA, glutathione (liposomal, evening)
• Curcumin + omega-3 (high EPA) for neuroinflammation
• Gut: prokinetic at bedtime, rotating botanicals for the SIBO pattern, then specific probiotic strains after the kill phase
• Continued nervous-system work

Months 5–9 — Optimization + maintenance.

• Continued methylation support at maintenance dose
• DUTCH re-run at month 4 and month 8
• Cognitive baseline retest at month 6 (clinic neurocognitive battery)
• Phased introduction of HBOT for residual brain-fog days (optional, patient preference)

The timeline

• Week 2: Bowels regular for the first time in years. Sleep onset improved.
• Week 6: First day at work without an afternoon crash. Word-finding still patchy.
• Week 10: Anxiety baseline noticeably calmer. Energy curve flatter.
• Month 4: "I feel like myself again." Cognitive battery — back to baseline.
• Month 6: Homocysteine 7.1, ferritin 68, D 52, B12 functional. DUTCH — methylation pattern normalized.
• Month 9: Maintained on low-dose protocol. Stress capacity higher than pre-symptom baseline.

<!-- CHART: Symptom severity, energy, sleep, and key labs across nine-month recovery -->

What this case is about

Three things to take from Sarah's story:

1. "Labs are fine" is often the standard labs don't pick this up. Her PCP wasn't wrong — her CBC, CMP, and thyroid were normal. The labs that named her problem weren't on the standard panel.
2. MTHFR matters, and the way it matters depends on the rest of your genetic profile. Compound heterozygous MTHFR with slow COMT needs a completely different methylation strategy than MTHFR with fast COMT. The "MTHFR is overhyped" reads and the "everyone needs methyl-B" reads are both wrong.
3. Sequencing is the difference between a protocol that works and one that flares. Open drainage first. Stabilize the nervous system. Start methylation low and slow with cofactors. Treat neuroinflammation when the foundation is in place. Re-test. Adjust.

This is the work DNA Precision was built for and what Health Decode is designed to surface earlier than month twelve.

---

Continue: Klinghardt — Practitioner Who Sees What Conventional Medicine Misses · Long COVID Is a Label, Not a Diagnosis · Brain fog root causes.

Patient details composite-anonymized. Clinical picture, lab values, and timeline are representative of multiple patients with the same presenting profile.